{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:40:33Z","timestamp":1768830033238,"version":"3.49.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T00:00:00Z","timestamp":1317081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/nrneph.2011.139","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T11:59:24Z","timestamp":1317124764000},"page":"624-634","source":"Crossref","is-referenced-by-count":28,"title":["Mineral and bone disorders in children with chronic kidney disease"],"prefix":"10.1038","volume":"7","author":[{"given":"Claus Peter","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Mehls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,27]]},"reference":[{"key":"BFnrneph2011139_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe, S. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69, 1945\u20131953 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ki.2010.316","volume":"78","author":"D Borzych","year":"2010","unstructured":"Borzych, D. et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int. 78, 1295\u20131304 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","volume":"106","author":"J Oh","year":"2002","unstructured":"Oh, J. et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106, 100\u2013105 (2002).","journal-title":"Circulation"},{"key":"BFnrneph2011139_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman, W. G. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478\u20131483 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2011139_CR5","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa031643","volume":"350","author":"SP McDonald","year":"2004","unstructured":"McDonald, S. P. & Craig, J. C. Long-term survival of children with end-stage renal disease. N. Engl. J. Med. 350, 2654\u20132662 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2011139_CR6","doi-asserted-by":"publisher","unstructured":"Shroff, R. et al. Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients. Pediatr. Nephrol. http:\/\/dx.doi.org\/10.1007\/s00467-011-1920-z .","DOI":"10.1007\/s00467-011-1920-z"},{"key":"BFnrneph2011139_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/j.1600-6143.2005.00938.x","volume":"5","author":"W Gwinner","year":"2005","unstructured":"Gwinner, W. et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am. J. Transplant. 5, 1934\u20131941 (2005).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph2011139_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/ki.1986.252","volume":"30","author":"JA Ramirez","year":"1986","unstructured":"Ramirez, J. A. et al. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 30, 753\u2013759 (1986).","journal-title":"Kidney Int."},{"issue":"Suppl. 1","key":"BFnrneph2011139_CR9","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.2215\/CJN.05970809","volume":"5","author":"DA Bushinsky","year":"2010","unstructured":"Bushinsky, D. A. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin. J. Am. Soc. Nephrol. 5 (Suppl. 1), S12\u2013S22 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR10","volume-title":"Pediatric reference ranges","author":"SJ Soldin","year":"2003","unstructured":"Soldin, S. J., Brugnara, C. & Wong, E. C. (eds) Pediatric reference ranges (AACC-Press, Washington, 2003)."},{"key":"BFnrneph2011139_CR11","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation. KDOQI Clinical Practice Guidelines for Nutrition in Children with CKD: 2008 Update. Am. J. Kidney Dis. 53 (Suppl. 2), S1\u2013S124 (2009).","DOI":"10.1053\/j.ajkd.2008.11.017"},{"key":"BFnrneph2011139_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/BF00858154","volume":"8","author":"J Brodehl","year":"1994","unstructured":"Brodehl, J. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr. Nephrol. 8, 645 (1994).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR13","volume-title":"Paediatric chemical pathology: clinical tests and references ranges","author":"BE Clayton","year":"1980","unstructured":"Clayton, B. E., Jenkins, P. & Round, J. M. (eds) Paediatric chemical pathology: clinical tests and references ranges (Blackwell Scientific, Oxford 1980)."},{"key":"BFnrneph2011139_CR14","first-page":"193","volume-title":"P\u00e4diatrie","author":"FC Sitzmann","year":"1995","unstructured":"Sitzmann, F. C. in P\u00e4diatrie (ed. Sitzmann, F. C.), 193 (Hippokrates Verlag, Stuttgart, 1995)."},{"key":"BFnrneph2011139_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1203\/PDR.0b013e3181bc3f60","volume":"66","author":"M H\u00e4usler","year":"2009","unstructured":"H\u00e4usler, M., Sch\u00e4fer, C., Osterwinter, C. & Jahnen-Dechent, W. The physiologic development of fetuin-a serum concentrations in children. Pediatr. Res. 66, 660\u2013664 (2009).","journal-title":"Pediatr. Res."},{"key":"BFnrneph2011139_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1258\/acb.2009.009037","volume":"46","author":"M Wigger","year":"2009","unstructured":"Wigger, M. et al. Fetuin-A serum concentrations in healthy children. Ann. Clin. Biochem. 46, 511\u2013513 (2009).","journal-title":"Ann. Clin. Biochem."},{"key":"BFnrneph2011139_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-003-1283-1","volume":"19","author":"S Picca","year":"2004","unstructured":"Picca, S. et al. Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone. Pediatr. Nephrol. 19, 71\u201376 (2004).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR18","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","volume":"70","author":"I Bhan","year":"2006","unstructured":"Bhan, I. et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int. 70, 1486\u20131494 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00467-005-2082-7","volume":"21","author":"G Klaus","year":"2006","unstructured":"Klaus, G. et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr. Nephrol. 21, 151\u2013159 (2006).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ki.1994.31","volume":"45","author":"IB Salusky","year":"1994","unstructured":"Salusky, I. B. et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD\/CCPD. Kidney Int. 45, 253\u2013258 (1994).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.5414\/CNP63284","volume":"63","author":"A Gal-Moscovici","year":"2005","unstructured":"Gal-Moscovici, A. & Popovtzer, M. M. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin. Nephrol. 63, 284\u2013289 (2005).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2011139_CR22","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1210\/jcem.84.11.6236","volume":"84","author":"MR John","year":"1999","unstructured":"John, M. R. et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84, 4287\u20134290 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1046\/j.1523-1755.2003.00915.x","volume":"63","author":"IB Salusky","year":"2003","unstructured":"Salusky, I. B. et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 63, 1801\u20131808 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00467-009-1143-8","volume":"24","author":"K Wesseling-Perry","year":"2009","unstructured":"Wesseling-Perry, K. et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr. Nephrol. 24, 1355\u20131361 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR25","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0085-2538(15)47156-X","volume":"58","author":"E Slatopolsky","year":"2000","unstructured":"Slatopolsky, E. et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 58, 753\u2013761 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR26","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/j.1523-1755.2005.00339.x","volume":"67","author":"SC Waller","year":"2005","unstructured":"Waller, S. C., Ridout, D., Cantor, T. & Rees, L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int. 67, 2338\u20132345 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1373\/clinchem.2006.071589","volume":"52","author":"T Cantor","year":"2006","unstructured":"Cantor, T., Yang, Z., Caraiani, N. & Ilamathi, E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin. Chem. 52, 1771\u20131776 (2006).","journal-title":"Clin. Chem."},{"key":"BFnrneph2011139_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2215\/CJN.09471209","volume":"5","author":"C Gardham","year":"2010","unstructured":"Gardham, C. et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin. J. Am. Soc. Nephrol. 5, 1261\u20131267 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR29","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 113, S1\u2013S130 (2009)."},{"key":"BFnrneph2011139_CR30","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation. K\/DOQI Clinical Practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am. J. Kidney Dis. 46 (Suppl. 1), 1\u2013122 (2005).","DOI":"10.1053\/j.ajkd.2005.07.028"},{"key":"BFnrneph2011139_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","volume":"53","author":"BD Kuizon","year":"1998","unstructured":"Kuizon, B. D. et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int. 53, 205\u2013211 (1998).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00467-003-1091-7","volume":"18","author":"CP Schmitt","year":"2003","unstructured":"Schmitt, C. P., Ardissino, G., Testa, S., Claris-Appiani, A. & Mehls, O. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr. Nephrol. 18, 440\u2013444 (2003).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR33","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/j.1523-1755.2005.00339.x","volume":"67","author":"SC Waller","year":"2005","unstructured":"Waller, S. C., Ridout, D., Cantor, T. & Rees, L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int. 67, 2338\u20132345 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00467-008-0838-6","volume":"23","author":"S Waller","year":"2008","unstructured":"Waller, S., Shroff, R., Freemont, A. J. & Rees, L. Bone histomorphometry in children prior to commencing renal replacement therapy. Pediatr. Nephrol. 23, 1523\u20131529 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR35","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00467-006-0348-3","volume":"22","author":"J Cansick","year":"2007","unstructured":"Cansick, J., Waller, S., Ridout, D. & Rees, L. Growth and PTH in prepubertal children on long-term dialysis. Pediatr. Nephrol. 22, 1349\u20131354 (2007).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ndt\/gfp565","volume":"25","author":"M Fischbach","year":"2010","unstructured":"Fischbach, M. et al. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol. Dial. Transplant. 25, 867\u2013873 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR37","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","volume":"54","author":"IB Salusky","year":"1998","unstructured":"Salusky, I. B. et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. 54, 907\u2013914 (1998).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR38","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2215\/CJN.01330210","volume":"5","author":"SA Bakkaloglu","year":"2010","unstructured":"Bakkaloglu, S. A. et al. Value of the new bone classification system in pediatric renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 5, 1860\u20131866 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR39","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1681\/ASN.2004100885","volume":"16","author":"IB Salusky","year":"2005","unstructured":"Salusky, I. B. et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J. Am. Soc. Nephrol. 16, 2501\u20132508 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1515\/JPEM.1999.12.6.879","volume":"12","author":"J Piscitelli","year":"1999","unstructured":"Piscitelli, J., Cabansag, M. R. & Silverstein, D. M. Correlation among markers of renal osteodystrophy in pediatric hemodialysis patients. J. Pediatr. Endocrinol. Metab. 12, 879\u2013886 (1999).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00774-010-0220-1","volume":"29","author":"A Christoforidis","year":"2011","unstructured":"Christoforidis, A. et al. Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease. J. Bone Miner. Metab. 29, 321\u2013327 (2011).","journal-title":"J. Bone Miner. Metab."},{"key":"BFnrneph2011139_CR42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00467-011-1870-5","volume":"26","author":"E Siomou","year":"2011","unstructured":"Siomou, E. et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr. Nephrol. 26, 1105\u20131114 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR43","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1651-2227.2000.tb00361.x","volume":"89","author":"H Zi\u00f3lkowska","year":"2000","unstructured":"Zi\u00f3lkowska, H. et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr. 89, 666\u2013671 (2000).","journal-title":"Acta Paediatr."},{"key":"BFnrneph2011139_CR44","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1359\/jbmr.080610","volume":"23","author":"A Fahrleitner-Pammer","year":"2008","unstructured":"Fahrleitner-Pammer, A. et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Miner. Res. 23, 1850\u20131858 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2011139_CR45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/sj.ki.5002716","volume":"73","author":"U Baber","year":"2008","unstructured":"Baber, U. et al. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 73, 615\u2013621 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000245643","volume":"29","author":"R Mohandas","year":"2010","unstructured":"Mohandas, R. & Segal, M. S. Endothelial progenitor cells and endothelial vesicles\u2014what is the significance for patients with chronic kidney disease. Blood Purif. 29, 158\u2013162 (2010).","journal-title":"Blood Purif."},{"key":"BFnrneph2011139_CR47","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1210\/jc.2009-1576","volume":"95","author":"J Bacchetta","year":"2010","unstructured":"Bacchetta, J. et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J. Clin. Endocrinol. Metab. 95, 1741\u20131748 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ki.2010.107","volume":"78","author":"M van Husen","year":"2010","unstructured":"van Husen, M. et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 78, 200\u2013206 (2010).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR49","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370\u20131378 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MNH.0b013e3283477a7b","volume":"20","author":"M Petkovich","year":"2011","unstructured":"Petkovich, M. & Jones, G. CYP24A1 and kidney disease. Curr. Opin. Nephrol. Hypertens. 20, 337\u2013344 (2011).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2011139_CR51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry, K. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 79, 112\u2013119 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR52","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson, T., Nisbeth, U., Ljunggren, O., J\u00fcppner, H. & Jonsson, K. B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64, 2272\u20132279 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"Guti\u00e9rrez, O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584\u2013592 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2011139_CR54","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf, M. et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J. Am. Soc. Nephrol. 22, 956\u2013966 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR55","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Guti\u00e9rrez","year":"2009","unstructured":"Guti\u00e9rrez, O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545\u20132552 (2009).","journal-title":"Circulation"},{"key":"BFnrneph2011139_CR56","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2215\/CJN.02560310","volume":"5","author":"M Kanbay","year":"2010","unstructured":"Kanbay, M. et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1780\u20131786 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR57","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.bone.2011.01.016","volume":"48","author":"P Manghat","year":"2011","unstructured":"Manghat, P. et al. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone 48, 1127\u20131132 (2011).","journal-title":"Bone"},{"key":"BFnrneph2011139_CR58","doi-asserted-by":"publisher","unstructured":"Wesseling-Perry, K., Tsai, E. W., Ettenger, R. B., J\u00fcppner, H. & Salusky, I. B. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfr126 .","DOI":"10.1093\/ndt\/gfr126"},{"key":"BFnrneph2011139_CR59","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1210\/jc.2008-0326","volume":"94","author":"K Wesseling-Perry","year":"2009","unstructured":"Wesseling-Perry, K. et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J. Clin. Endocrinol. Metab. 94, 511\u2013517 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR60","doi-asserted-by":"publisher","first-page":"364890","DOI":"10.4061\/2011\/364890","volume":"2011","author":"D Russo","year":"2011","unstructured":"Russo, D. & Battaglia, Y. Clinical significance of FGF-23 in patients with CKD. Int. J. Nephrol. 2011, 364890 (2011).","journal-title":"Int. J. Nephrol."},{"key":"BFnrneph2011139_CR61","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-004-1465-5","volume":"19","author":"E Sch\u00f6nau","year":"2004","unstructured":"Sch\u00f6nau, E. The peak bone mass concept: is it still relevant? Pediatr. Nephrol. 19, 825\u2013831 (2004).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00467-009-1248-0","volume":"25","author":"LT Weber","year":"2010","unstructured":"Weber, L. T. & Mehls, O. Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr. Nephrol. 25, 3\u20135 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00467-010-1745-1","volume":"26","author":"J Bacchetta","year":"2011","unstructured":"Bacchetta, J. et al. Bone assessment in children with chronic kidney disease: data from two new bone imaging techniques in a single-center pilot study. Pediatr. Nephrol. 26, 587\u2013595 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR64","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1210\/jc.2009-1913","volume":"95","author":"MB Leonard","year":"2010","unstructured":"Leonard, M. B. et al. Effects of sex, race, and puberty on cortical bone and the functional muscle bone unit in children, adolescents, and young adults. J. Clin. Endocrinol. Metab. 95, 1681\u20131689 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR65","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1651-2227.2000.tb00361.x","volume":"89","author":"H Zi\u00f3lkowska","year":"2000","unstructured":"Zi\u00f3lkowska, H. et al. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr. 89, 666\u2013671 (2000).","journal-title":"Acta Paediatr."},{"key":"BFnrneph2011139_CR66","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ki.1994.31","volume":"45","author":"IB Salusky","year":"1994","unstructured":"Salusky, I. B. et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD\/CCPD. Kidney Int. 45, 253\u2013258 (1994).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","volume":"26","author":"FH Glorieux","year":"2000","unstructured":"Glorieux, F. H. et al. Normative data for iliac bone histomorphometry in growing children. Bone 26, 103\u2013109 (2000).","journal-title":"Bone"},{"key":"BFnrneph2011139_CR68","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair, R. E. et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am. J. Kidney Dis. 45, 1026\u20131033 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR69","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00467-010-1639-2","volume":"25","author":"P Hari","year":"2010","unstructured":"Hari, P. et al. Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr. Nephrol. 25, 2483\u20132488 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR70","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1542\/peds.2008-0634","volume":"123","author":"FN Ali","year":"2009","unstructured":"Ali, F. N., Arguelles, L. M., Langman, C. B. & Price, H. E. Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123, 791\u2013796 (2009).","journal-title":"Pediatrics"},{"key":"BFnrneph2011139_CR71","doi-asserted-by":"publisher","unstructured":"Shroff, R. et al. Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients. Pediatr. Nephrol. http:\/\/dx.doi.org\/10.1007\/s00467-011-1920-z .","DOI":"10.1007\/s00467-011-1920-z"},{"key":"BFnrneph2011139_CR72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266\u2013281 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2011139_CR73","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.06510909","volume":"5","author":"PJ Matias","year":"2010","unstructured":"Matias, P. J. et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 5, 905\u2013911 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR74","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00467-008-0842-x","volume":"23","author":"S Menon","year":"2008","unstructured":"Menon, S., Valentini, R. P., Hidalgo, G., Peschansky, L. & Mattoo, T. K. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr. Nephrol. 23, 1831\u20131836 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR75","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1681\/ASN.2007090993","volume":"19","author":"R Shroff","year":"2008","unstructured":"Shroff, R. et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 19, 1239\u20131246 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR76","doi-asserted-by":"publisher","first-page":"582S","DOI":"10.1093\/ajcn\/88.2.582S","volume":"88","author":"G Jones","year":"2008","unstructured":"Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 88, 582S\u2013586S (2008).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrneph2011139_CR77","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng, M. et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349, 446\u2013456 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2011139_CR78","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","volume":"70","author":"F Tentori","year":"2006","unstructured":"Tentori, F. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858\u20131865 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR79","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2165\/11536310-000000000-00000","volume":"30","author":"M Nuijten","year":"2010","unstructured":"Nuijten, M., Andress, D. L., Marx, S. E., Curry, A. S. & Sterz, R. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin. Drug Investig. 30, 545\u2013557 (2010).","journal-title":"Clin. Drug Investig."},{"key":"BFnrneph2011139_CR80","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague, S. M., Llach, F., Amdahl, M., Taccetta, C. & Batlle, D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63, 1483\u20131490 (2003).","journal-title":"Kidney Int."},{"issue":"2 Suppl. 2","key":"BFnrneph2011139_CR81","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","volume":"32","author":"F Llach","year":"1998","unstructured":"Llach, F. et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am. J. Kidney Dis. 32 (2 Suppl. 2), S48\u2013S54 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR82","doi-asserted-by":"crossref","unstructured":"Palmer, S. C. et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews Issue 7. Art. No.: CD005633. doi:10.1002\/14651858.CD005633.pub2 (2009).","DOI":"10.1002\/14651858.CD005633.pub2"},{"key":"BFnrneph2011139_CR83","doi-asserted-by":"crossref","unstructured":"Palmer, S. C. et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews Issue 7 Art. No.: CD008175 doi:10.1002\/14651858.CD008175 (2009).","DOI":"10.1002\/14651858.CD008175"},{"key":"BFnrneph2011139_CR84","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"JL Finch","year":"1999","unstructured":"Finch, J. L., Brown, A. J. & Slatopolsky, E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. 10, 980\u2013985 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR85","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1067\/mlc.2002.122819","volume":"139","author":"AJ Brown","year":"2002","unstructured":"Brown, A. J., Finch, J. & Slatopolsky, E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J. Lab. Clin. Med. 139, 279\u2013284 (2002).","journal-title":"J. Lab. Clin. Med."},{"key":"BFnrneph2011139_CR86","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.ki.5002406","volume":"72","author":"M Mizobuchi","year":"2007","unstructured":"Mizobuchi, M., Finch, J. L., Martin, D. R. & Slatopolsky, E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72, 709\u2013715 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR87","doi-asserted-by":"publisher","first-page":"F772","DOI":"10.1152\/ajprenal.00042.2010","volume":"300","author":"LE Becker","year":"2011","unstructured":"Becker, L. E. et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am. J. Physiol. Renal Physiol. 300, F772\u2013F782 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2011139_CR88","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/sj.ki.5002458","volume":"72","author":"JM Repo","year":"2007","unstructured":"Repo, J. M. et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int. 72, 977\u2013984 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR89","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","volume":"49","author":"LA Greenbaum","year":"2007","unstructured":"Greenbaum, L. A. et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am. J. Kidney Dis. 49, 814\u2013823 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR90","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00467-006-0204-5","volume":"21","author":"W Seeherunvong","year":"2006","unstructured":"Seeherunvong, W. et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr. Nephrol. 21, 1434\u20131439 (2006).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR91","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1365-2125.2003.01809.x","volume":"55","author":"S Tsuruoka","year":"2003","unstructured":"Tsuruoka, S., Wakaumi, M., Sugimoto, K., Saito, T. & Fujimura, A. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study. Br. J. Clin. Pharmacol. 55, 531\u2013537 (2003).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph2011139_CR92","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1053\/j.ajkd.2005.12.039","volume":"47","author":"AK Pieper","year":"2006","unstructured":"Pieper, A. K. et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am. J. Kidney Dis. 47, 625\u2013635 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR93","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00467-009-1328-1","volume":"25","author":"E Gonzalez","year":"2010","unstructured":"Gonzalez, E., Schomberg, J., Amin, N., Salusky, I. B. & Zaritsky, J. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr. Nephrol. 25, 373\u2013375 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR94","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow, G. M., Burke, S. K. & Raggi, P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62, 245\u2013252 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR95","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","volume":"57","author":"T Kakuta","year":"2011","unstructured":"Kakuta, T. et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am. J. Kidney Dis. 57, 422\u2013431 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR96","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/sj.ki.5002059","volume":"71","author":"GA Block","year":"2007","unstructured":"Block, G. A., Raggi, P., Bellasi, A., Kooienga, L. & Spiegel, D. M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 71, 438\u2013441 (2007).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR97","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","volume":"54","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan, S. D., Palmer, S. C., Craig, J. C., Elder, G. J. & Strippoli, G. F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 54, 619\u2013637 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2011139_CR98","first-page":"286","volume":"71","author":"AJ Hutchison","year":"2009","unstructured":"Hutchison, A. J., Barnett, M. E., Krause, R. J. & Siami, G. A. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin. Nephrol. 71, 286\u2013295 (2009).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2011139_CR99","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1523-1755.2005.00171.x","volume":"67","author":"B Lacour","year":"2005","unstructured":"Lacour, B. et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 67, 1062\u20131069 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR100","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1093\/ndt\/gfp364","volume":"24","author":"RL Davis","year":"2009","unstructured":"Davis, R. L. & Abraham, J. L. Lanthanum deposition in a dialysis patient. Nephrol. Dial. Transplant. 24, 3247\u20133250 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR101","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","volume":"21","author":"GB Spasovski","year":"2006","unstructured":"Spasovski, G. B. et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol. Dial. Transplant. 21, 2217\u20132224 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR102","doi-asserted-by":"crossref","unstructured":"Strippoli, G. F., Tong, A., Palmer, S. C., Elder, G. & Craig, J. C. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews Issue 18 Art. No.: CD006254 doi:10.1002\/14651858.CD006254 (2006).","DOI":"10.1002\/14651858.CD006254"},{"key":"BFnrneph2011139_CR103","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/ndt\/gfn654","volume":"24","author":"M Meola","year":"2009","unstructured":"Meola, M., Petrucci, I. & Barsotti, G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 24, 982\u2013989 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR104","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi, P. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol. Dial. Transplant. 26, 1327\u20131339 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR105","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","volume":"23","author":"J Muscheites","year":"2008","unstructured":"Muscheites, J. et al. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr. Nephrol. 23, 1823\u20131829 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR106","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00467-007-0742-5","volume":"23","author":"DM Silverstein","year":"2008","unstructured":"Silverstein, D. M. et al. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr. Nephrol. 23, 1817\u20131822 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR107","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/ndt\/gfp211","volume":"24","author":"J Bacchetta","year":"2009","unstructured":"Bacchetta, J. et al. Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol. Dial. Transplant. 24, 2595\u20132598 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR108","unstructured":"European Medicines Agency European Assessment Report MIMPARA [online] , (2009)."},{"key":"BFnrneph2011139_CR109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1096\/fj.03-0294fje","volume":"18","author":"S Wu","year":"2004","unstructured":"Wu, S., Palese, T., Mishra, O. P., Delivoria-Papadopoulos, M. & De Luca, F. Effects of Ca2+ sensing receptor activation in the growth plate. FASEB J. 18, 143\u2013145 (2004).","journal-title":"FASEB J."},{"key":"BFnrneph2011139_CR110","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1210\/en.2005-0437","volume":"146","author":"L Rodriguez","year":"2005","unstructured":"Rodriguez, L., Cheng, Z., Chen, T. H., Tu, C. & Chang, W. Extracellular calcium and parathyroid hormone-related peptide signaling modulate the pace of growth plate chondrocyte differentiation. Endocrinology 146, 4597\u20134608 (2005).","journal-title":"Endocrinology"},{"key":"BFnrneph2011139_CR111","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2000.00993.x","volume":"57","author":"CP Schmitt","year":"2000","unstructured":"Schmitt, C. P. et al. Intermittent administration of parathyroid hormone (1\u201337) improves growth and bone mineral density in uremic rats. Kidney Int. 57, 1484\u20131492 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR112","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1210\/endo.137.11.8895385","volume":"137","author":"K Lee","year":"1996","unstructured":"Lee, K. et al. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 137, 5109\u20135118 (1996).","journal-title":"Endocrinology"},{"key":"BFnrneph2011139_CR113","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1126\/science.273.5275.663","volume":"273","author":"B Lanske","year":"1996","unstructured":"Lanske, B. et al. PTH\/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273, 663\u2013666 (1996).","journal-title":"Science"},{"key":"BFnrneph2011139_CR114","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1210\/endo.142.9.8364","volume":"142","author":"SC Garner","year":"2001","unstructured":"Garner, S. C., Pi, M., Tu, Q. & Quarles, L. D. Rickets in cation-sensing receptor-deficient mice: an unexpected skeletal phenotype. Endocrinology 142, 3996\u20134005 (2001).","journal-title":"Endocrinology"},{"key":"BFnrneph2011139_CR115","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI17416","volume":"111","author":"CH Kos","year":"2003","unstructured":"Kos, C. H. et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J. Clin. Invest. 111, 1021\u20131028 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2011139_CR116","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1172\/JCI200317054","volume":"111","author":"Q Tu","year":"2003","unstructured":"Tu, Q. et al. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J. Clin. Invest. 111, 1029\u20131037 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2011139_CR117","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1210\/jc.2005-2605","volume":"91","author":"SD Mittelman","year":"2006","unstructured":"Mittelman, S. D. et al. A hypocalcemic child with a novel activating mutation of the calcium-sensing receptor gene: successful treatment with recombinant human parathyroid hormone. J. Clin. Endocrinol. Metab. 91, 2474\u20132479 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR118","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1515\/JPEM.2005.18.7.689","volume":"18","author":"CP Burren","year":"2005","unstructured":"Burren, C. P., Curley, A., Christie, P., Rodda, C. P. & Thakker, R. V. A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. J. Pediatr. Endocrinol. Metab. 18, 689\u2013699 (2005).","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"BFnrneph2011139_CR119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ajmg.a.30403","volume":"132","author":"A Uckun-Kitapci","year":"2005","unstructured":"Uckun-Kitapci, A., Underwood, L. E., Zhang, J. & Moats-Staats, B. A novel mutation (E767K) in the second extracellular loop of the calcium sensing receptor in a family with autosomal dominant hypocalcemia. Am. J. Med. Genet. 132, 125\u2013129 (2005).","journal-title":"Am. J. Med. Genet."},{"key":"BFnrneph2011139_CR120","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/ndt\/gfn143","volume":"23","author":"K Nakagawa","year":"2008","unstructured":"Nakagawa, K. et al. Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia. Nephrol. Dial. Transplant. 23, 2761\u20132767 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2011139_CR121","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00467-009-1294-7","volume":"25","author":"C Platt","year":"2010","unstructured":"Platt, C. et al. Middle-term use of cinacalcet in paediatric dialysis patients. Pediatr. Nephrol. 25, 143\u2013148 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2011139_CR122","unstructured":"DrugLib.com Well-designed clinical trials related to Sensipar (cinacalcet) [online] , (2011)."},{"key":"BFnrneph2011139_CR123","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/jpet.110.178681","volume":"337","author":"C Henley 3rd","year":"2011","unstructured":"Henley, C. 3rd et al. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion. J. Pharmacol. Exp. Ther. 337, 681\u2013691 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrneph2011139_CR124","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/ki.2011.105","volume":"80","author":"J Oh","year":"2011","unstructured":"Oh, J. et al. Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int. 80, 483\u2013492 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2011139_CR125","doi-asserted-by":"publisher","first-page":"F1315","DOI":"10.1152\/ajprenal.00552.2009","volume":"298","author":"JL Finch","year":"2010","unstructured":"Finch, J. L. et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am. J. Physiol. Renal Physiol. 298, F1315\u2013F1322 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2011139_CR126","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham, J., Locatelli, F. & Rodriguez, M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 6, 913\u2013921 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2011139_CR127","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1093\/ndt\/gfq074","volume":"25","author":"B Schaefer","year":"2010","unstructured":"Schaefer, B. et al. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease. Nephrol. Dial. Transplant. 25, 2590\u20132595 (2010).","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.139","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:35:23Z","timestamp":1684470923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2011.139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,27]]},"references-count":127,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BFnrneph2011139"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2011.139","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,27]]}}}